2020 (137 POSTS)

Cohen SS, Roger VL, Weston SA, Jiang R, Movva N, Yusuf AA, Chamberlain AM. 2020. Evaluation of claims-based computable phenotypes to identify heart failure patients with preserved ejection fraction. Pharmacol Res Persp 8(6):e00676; doi: 10.1002/prp2.676.

View Abstract

Wheeler MW, Blessinger T, Shao K, Allen BC, Olszyk L, Davis JA, Gift JS. 2020. Quantitative risk assessment: Developing a Bayesian approach to dichotomous dose–response uncertainty. Risk Anal 40(9):1706-22; doi: 10.1111/risa.13537. PMCID: PMC7722241.

View Abstract

Bylsma LC, Gillezeau C, Garawin TA, Kelsh MA, Fryzek JP, Sangaré L, et al. 2020. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med 9(3):1044–1057.

View Abstract

Li S, Liu J, Gong T, Guo H, Gawade PL, Kelsh MA, et al. 2020. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. J Geriatr Oncol 11(8):1309–1315.

View Abstract

Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA, et al. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. 2020. Curr Med Res Opin 36(9):1519–1527.

View Abstract

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. 2020. Support Care Cancer 28(9):4413–4424.

View Abstract

Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA. 2020. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J Cancer Edu 35(1):178–186.

View Abstract

Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA, et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478.

View Abstract

Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, … Kelsh M, et al. 2020. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871–e882.

View Abstract

Eichenbaum G, Yang K, Gebremichael Y, Howell BA, Murray FJ, Jacobson-Kram D, Jaeschke H, Kuffner E, Gelotte CK, Lai JCK, Wikoff D, Atillasoy E. 2020. Application of the DILIsym® Quantitative Systems Toxicology drug-induced liver injury model to evaluate the carcinogenic hazard potential of acetaminophen. Regul Toxicol Pharmacol 118(Dec):104788; doi: 10.1016/j.yrtph.2020.104788.

View Abstract

Fryzek J, Bylsma L, Mease K, Movva N, Welsh BT, Wood M. 2020. Critical insights into nonclinical toxicology and real-world evidence essential for a successful rare disease product launch. EpidStrategies, Inc. White Paper.

View Abstract

Mullen KR, Rivera BN, Tidwell AG, Ivanek R, Anderson KA, Ainsworth DM. 2020. Environmental surveillance and adverse neonatal health outcomes in foals born near unconventional natural gas development activity. Sci Tot Environ 731(Aug 20):138497; doi: 10.1016/j.scitotenv.2020.138497. PMID: 32434096.

View Abstract

Gage SM, Reichert H. 2020. Determining the incidence of needle-related complications in hemodialysis access: We need a better system. J Vascular Access.

View Abstract

Elbeddini A, Hooda N, Yang L. 2020. Role of Canadian pharmacists in managing drug shortage concerns amid the COVID-19 pandemic. Canad Pharmacists J 153(4)198-203; doi: 10.1177/1715163520929387.

View Abstract

Conrad F, Schober M, Nielsen D, Reichert H. 2020. Virtual interviewers, social identities, and survey measurement error. Chap 11 in: Olson K, Smyth JD, Dykema J, et al. (eds), Interviewer Effects from a Total Survey Error Perspective. CRC Press, Boca Raton, FL.

Suh M, Jiang X, Movva N, Fryzek J, Bylsma L, Rizzo C, Nelson CB. Hospitalizations and emergency department visits for respiratory syncytial virus among infants aged <1 year in the United States: An analysis of nationwide inpatient and emergency room data. Presentation to IDWeek Virtual Conference on Infectious Disease, October 2020.

View Abstract

Fergie J, Gonzales T, Suh M, Jiang X, Fryzek J, Howard A, Bloomfield A. 2020. Respiratory syncytial virus hospitalizations (RSVH) and all-cause bronchiolitis hospitalizations (BH) among children aged ≤24 months at the start of RSV season with bronchopulmonary dysplasia/chronic lung disease of prematurity (BPD/CLDP) before and after the 2014 American Academy of Pediatrics (AAP) policy. Presentation to IDWeek Virtual Conference on Infectious Disease, October 2020.

View Abstract

Fergie J, Gonzales T, Suh M, Jiang X, Fryzek J, Howard A, Bloomfield A. Medically attended respiratory syncytial virus hospitalizations (RSVH) and all-cause bronchiolitis hospitalizations (BH) among children aged ≤24 months at RSV season start with higher-risk congenital heart disease (CHD) before and after the 2014 American Academy of Pediatrics (AAP) policy. Presentation to IDWeek Conference on Infectious Disease, Virtual, October 2020.

Loper J, Lewis KH, Rothberg A, Auriemma A, Coburn SL, Cohen SS, Matarese L, Pories WJ, Jiang X, Periman S, Ard JD. Weight change in participants completing meal replacement program is related to level of engagement. Obesity Week Conference, Virtual, 2020.

Rankin DA, Haddadin Z, Lipworth L, Fryzek J, Suh M, Shepard DS, McHenry R, Varjabedian R, Fernandez KN, Rizzo C, Nelson CB, Halasa NB. Comparison of clinical presentations and burden of respiratory syncytial virus in infants across three distinct healthcare settings. IDWeek Virtual Conference on Infectious Disease, October 2020.

View Abstract